These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38825408)

  • 1. Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
    Nally E; Young M; Wells C; Fairhead R; Baines K; Cheney-Lowe H; Jackson-Spence F; Powles T
    Eur Urol Focus; 2024 Mar; 10(2):219-221. PubMed ID: 38825408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.
    Klümper N; Eckstein M
    Eur Urol Focus; 2024 Mar; 10(2):224-226. PubMed ID: 38631991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity in
    Chu CE; Sjöström M; Egusa EA; Gibb EA; Badura ML; Zhu J; Koshkin VS; Stohr BA; Meng MV; Pruthi RS; Friedlander TW; Lotan Y; Black PC; Porten SP; Feng FY; Chou J
    Clin Cancer Res; 2021 Sep; 27(18):5123-5130. PubMed ID: 34108177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
    Bellmunt J; Nadal R
    Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
    Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
    J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
    Zhu X; Koshkin VS
    Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Klümper N; Tran NK; Zschäbitz S; Hahn O; Büttner T; Roghmann F; Bolenz C; Zengerling F; Schwab C; Nagy D; Toma M; Kristiansen G; Heers H; Ivanyi P; Niegisch G; Grunewald CM; Darr C; Farid A; Schlack K; Abbas M; Aydogdu C; Casuscelli J; Mokry T; Mayr M; Niedersüß-Beke D; Rausch S; Dietrich D; Saal J; Ellinger J; Ritter M; Alajati A; Kuppe C; Meeks J; Vera Badillo FE; Nakauma-González JA; Boormans J; Junker K; Hartmann A; Grünwald V; Hölzel M; Eckstein M
    J Clin Oncol; 2024 Jul; 42(20):2446-2455. PubMed ID: 38657187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.
    Drake MJ; Birder LA
    Eur Urol; 2024 Aug; 86(2):183-184. PubMed ID: 38538426
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA Approves First Agent to Treat Locally Advanced, Metastatic Urothelial Cancer.
    Kahl KL
    Oncology (Williston Park); 2020 Jan; 34(1):11. PubMed ID: 32645199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
    Matte P; Campedel L
    Bull Cancer; 2022; 109(7-8):738-740. PubMed ID: 35606195
    [No Abstract]   [Full Text] [Related]  

  • 14. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
    Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
    Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
    Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
    J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
    [No Abstract]   [Full Text] [Related]  

  • 16. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
    Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
    Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
    [No Abstract]   [Full Text] [Related]  

  • 18. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
    Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Brown JR; Koshkin VS
    Eur Urol Focus; 2024 Mar; 10(2):231-233. PubMed ID: 38797658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new era in the treatment of urothelial carcinoma.
    Faltas B
    Urol Oncol; 2023 Oct; 41(10):395-397. PubMed ID: 37833099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.